This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: AIZ GLW JNJ LLY MRK

Stocks in this article: AIZ GLW JNJ LLY MRK


Assurant (AIZ) was upgraded at Bank of America/Merrill Lynch to neutral. $60 price target. Company is seeing a pricing overhang easing in Florida, BofA/Merrill said.

Chesapeake Energy (CHK) was downgraded at Stifel Nicolaus to hold from buy. Valuation call, given low expectations for production growth, Stifel Nicolaus said.

Emcor (EME) was upgraded at DA Davidson to buy from neutral. Company is leveraged to a recovering nonresidential construction environment, DA Davidson said.

Corning (GLW) downgraded at Piper Jaffray to neutral from overweight. $14 price target. Company lacks exposure to new product cycle in display.

JB Hunt (JBHT) was upgraded at Bank of America/Merrill Lynch to buy from neutral. $81 price target. Company offers a strong secular growth story, BofA/Merrill said.

Johnson & Johnson (JNJ) was upgraded at Goldman Sachs to neutral from sell. Pharma outlook is improving, Goldman said. $95 price target.

Life Technologies (LIFE) was downgraded to hold at TheStreet Ratings.

Eli Lilly (LLY) was downgraded at Jefferies to underperform from buy. Estimates were also lowered, given worsening business environment and disappointing R&D productivity, Jefferies said. $40 price target.

L Brands (LTD) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Comp weakness persists and inventories are building, Credit Suisse said.

Merck (MRK) was downgraded at Jefferies to hold from buy. Estimates were also decreased on weak business environment and unimpressive cost-cutting initiatives, Jefferies said. $50 price target.

Pharmacyclics (PCYC) was upgraded at Goldman Sachs to buy from neutral. $170 price target. ibruttinib could generate $7.5 billion of peak annual sales, Goldman said.

Premier Exhibitions (PRXI) was downgraded to sell at TheStreet Ratings.

Sonoco (SON) was downgraded at Goldman Sachs to sell from neutral. Company will likely grow slower than its peers over the next few quarters, Goldman said.

Stock Comments / EPS Changes

Calpine (CPN) estimates, price target were reduced at UBS. Estimates were reduced through 2014. Company lowered its guidance, UBS said. Buy rating and new $22 price target.

Lowe's (LOW) estimates, target upped at Credit Suisse. Estimates were boosted through 2015. Higher comp sales are driving gross margin expansion. Outperform rating and new $55 price target, Credit Suisse said.

Methanex (MEOH) estimates, price target were raised at UBS. Shares are now seen reaching $59. Estimates were also increased, as the company is seeing higher reference pricing, UBS said. Buy rating.

Micron (MU) estimates were increased at Jefferies. Elpida and DRAM ASPs contributing to income and gross margin, Jefferies said. Buy rating and $30 price target.

Micron estimates, price target were increased at UBS. DRAM pricing is moving higher, UBS said. Buy rating and new $23 price target.

>To submit a news tip, email:

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs